Search

MediciNova Inc

Gesloten

SectorGezondheidszorg

1.54 1.32

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

1.45

Max

1.56

Belangrijke statistieken

By Trading Economics

Inkomsten

-4.9B

-4.9B

Verkoop

271K

458K

EPS

-0.05

Winstmarge

-1,068,366.946

Werknemers

6

EBITDA

5.1K

-2.5M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+422.88% upside

Dividenden

By Acuity

Volgende Winsten

10 nov 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

65M

Vorige openingsprijs

0.22

Vorige sluitingsprijs

1.54

Nieuwssentiment

By Acuity

50%

50%

150 / 340 Rangschikking in Healthcare

MediciNova Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

24 aug 2026, 20:02 UTC

MediciNova Inc shares are higher today, continuing a strong upward trend since Friday's close. The stock remains near the upper end of its one-month range.

21 aug 2026, 19:56 UTC

MediciNova Inc's shares are higher today, continuing a positive trend. The stock is trading above its 20-day moving average amid gains in the cryptocurrency sector.

20 aug 2026, 19:16 UTC

MediciNova Inc. shares are lower today, having previously declined significantly before recovering. The price remains above its 20-day moving average.

18 aug 2026, 19:56 UTC

MediciNova Inc shares are higher, reflecting positive market momentum. The stock remains above its 20-day moving average and near the upper end of its one-month range.

17 aug 2026, 19:56 UTC

News

MediciNova shares are higher as the company reported earnings of -$0.05 per share, surpassing estimates and generating $0.46 million in revenue.

13 aug 2026, 19:26 UTC

MediciNova Inc shares are lower amid broader market pressure from rising jobless claims and stabilizing inflation indicators. The stock trades near its one-month range low.

12 aug 2026, 19:56 UTC

MediciNova Inc. shares are trading roughly flat with no specific news identified, remaining near the lower end of their one-month trading range.

11 aug 2026, 20:06 UTC

MediciNova Inc. shares are roughly flat, showing little movement since Monday's close and positioned near the lower end of their one-month trading range.

10 aug 2026, 19:46 UTC

MediciNova Inc shares are lower today, continuing a downward trend since Friday. Broader market sentiment is affected by recent U.S. employment data.

7 aug 2026, 19:46 UTC

MediciNova Inc. shares are higher today, recovering from earlier losses. The stock is trading around the middle of its one-month range.

6 aug 2026, 20:13 UTC

MediciNova Inc shares are higher in after-market trading, reflecting strength since Thursday's close amid rising U.S. Treasury yields and a hawkish Fed outlook.

4 aug 2026, 19:36 UTC

MediciNova Inc. shares are trading roughly flat amid broader market reactions to a decline in U.S. core factory orders and ongoing strength in AI sectors.

3 aug 2026, 20:06 UTC

MediciNova Inc. shares are lower, continuing a decline since Friday's close, despite positive movements in major indices like the S&P 500 and Nasdaq 100.

31 jul 2026, 19:56 UTC

Shares of MediciNova Inc. are lower during Friday's session, following a routine decline after an early high. The stock is below its 20-day moving average.

30 jul 2026, 20:51 UTC

MediciNova Inc's shares are lower in after-market hours, reflecting a broader decline in the Biotechnology sub-sector. The asset is near its one-month trading range low.

29 jul 2026, 20:09 UTC

MediciNova Inc shares are lower today, continuing a decline since Tuesday's close, and remain near their opening low amid broader market trends.

28 jul 2026, 18:46 UTC

MediciNova Inc. shares are trading higher today, remaining above Monday's close despite settling back from earlier gains during the session.

27 jul 2026, 19:06 UTC

MediciNova Inc. shares are lower today, reflecting broader market trends amid a significant decline in crude oil prices following eased geopolitical tensions.

24 jul 2026, 23:02 UTC

MediciNova Inc shares increased in after-hours trading, reflecting strong performance since Friday's close, despite mixed market sentiment and no specific company news.

23 jul 2026, 20:06 UTC

MediciNova Inc. shares are lower today, continuing a six-session decline amid routine volatility and remaining significantly below the 20-day moving average.

21 jul 2026, 19:21 UTC

MediciNova Inc. shares are lower amid no specific news, continuing a trend below the 20-day moving average over the past three sessions.

Peer Vergelijking

Prijswijziging

MediciNova Inc Prognose

Koersdoel

By TipRanks

422.88% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 8 USD  422.88%

Hoogste 10 USD

Laagste 6 USD

Gebaseerd op 2 Wall Street-analisten die 12-maands prijsdoelen bieden voor MediciNova Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

2 ratings

2

Buy

0

Hold

0

Sell

Sentiment

By Acuity

150 / 340 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over MediciNova Inc

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.
help-icon Live chat